Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical 2026 Midterm Financial Results | Details of Revenue and Profit
Chugai Pharmaceutical achieved net sales of approximately 663.3 billion yen (up 14.7% YoY) for the second quarter (midterm) of the fiscal year ending December 2026, maintaining solid performance. Operating income also grew significantly to approximately 319.6 billion yen (+16.9%), and net profit has increased substantially, drawing attention to shareholder returns and future business development.
Key Figures
- Net Sales: 66,330 million yen (up 14.7% YoY)
- Operating Income: 31,960 million yen (up 16.9% YoY)
- Net Profit: 23,170 million yen (up 23.2% YoY)
AI要約
Outlook and Impact on Shareholders
Chugai Pharmaceutical continues to promote innovative drug development and global expansion, with a forecast of steady performance for the full fiscal year 2026. Shareholder return measures such as dividend increases and share buybacks are under consideration, positioning the company as an attractive investment. Anticipated new drug approvals and clinical trial advancements are expected to further strengthen the revenue base.
Profit Margin Analysis
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
